	US 12,350,286 B2
	Polypeptides directed against viral infection and uses thereof
Trushar R. Patel, Lethbridge (CA); Carla Stephanie Coffin, Calgary (CA); Vanessa Meier-Stephenson, Calgary (CA); and Maulik D. Badmalia, Lethbridge (CA)
Assigned to QUADRUMIX BIOTECHNOLOGY INC., Alberta (CA)
Appl. No. 17/425,791
Filed by QUADRUMIX BIOTECHNOLOGY INC., Lethbridge (CA)
PCT Filed Feb. 25, 2021, PCT No. PCT/CA2021/050234 § 371(c)(1), (2) Date Jul. 26, 2021, PCT Pub. No. WO2021/168575, PCT Pub. Date Sep. 2, 2021.
Claims priority of provisional application 62/982,474, filed on Feb. 27, 2020.
Prior Publication US 2023/0218656 A1, Jul. 13, 2023
Int. Cl. A61K 31/713 (2006.01); A61K 47/68 (2017.01); A61P 31/20 (2006.01)

CPC A61K 31/713 (2013.01) [A61K 47/6839 (2017.08); A61P 31/20 (2018.01)]

25 Claims

1. At least one polypeptide comprising at least one antiviral single domain antibody for targeting a guanine-rich region of viral DNA, wherein the at least one antiviral single domain antibody comprises an anti-Hepatitis B Virus (HBV)single domain antibody comprising amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 10, 11, 12, 13, 14, 15, 16 and 17.